We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pfizer Inc. (PFE - Free Report) is one of the most well-known names in the pharmaceutical sector not just for its medicines and vaccines but also for its consumer healthcare products. This New York-based company is well known for products like Prevnar, Lyrica, Lipitor and Celebrex among others.
However, like many of its peers, PFE is facing generic competition and pricing pressure for several products like Lipitor, Norvasc, Protonix, Camptosar, Celebrex and Zoloft. The influx of generic competition will not only put downward pressure on the company’s pricing, it will also result in gross margins contracting.
In this scenario, investor focus remains on late-stage pipeline candidates and their commercial potential and performance of new products apart from the usual top-and bottom-line numbers. Pfizer is also looking to strengthen its portfolio through the acquisition of Hospira.
PFE has a pretty good earnings track record with the company delivering positive earnings surprises in each of the last four quarters with an average surprise of 12.8%.
Currently, PFE has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: PFE beat on second quarter earnings which came in at 64 cents while our consensus called for EPS of 62 cents.
Revenue: Revenues were also above expectations. Pfizer posted revenues of $13.1 billion, compared to our consensus estimate of $12.9 billion. Unfavorable currency movement cut Pfizer’s second quarter revenues by 3% ($302 million).
Maintains Guidance: Pfizer continues to expect earnings of $2.38 - $2.48 per share on revenues of $51 billion - $53 billion. The Zacks Consensus Estimate for earnings and revenues are currently $2.46 per share and $52.6 billion, respectively.
Check back later for our full write up on this PFE earnings report!
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Pfizer (PFE) Beats on Q2 Earnings and Revenues
Pfizer Inc. (PFE - Free Report) is one of the most well-known names in the pharmaceutical sector not just for its medicines and vaccines but also for its consumer healthcare products. This New York-based company is well known for products like Prevnar, Lyrica, Lipitor and Celebrex among others.
However, like many of its peers, PFE is facing generic competition and pricing pressure for several products like Lipitor, Norvasc, Protonix, Camptosar, Celebrex and Zoloft. The influx of generic competition will not only put downward pressure on the company’s pricing, it will also result in gross margins contracting.
In this scenario, investor focus remains on late-stage pipeline candidates and their commercial potential and performance of new products apart from the usual top-and bottom-line numbers. Pfizer is also looking to strengthen its portfolio through the acquisition of Hospira.
PFE has a pretty good earnings track record with the company delivering positive earnings surprises in each of the last four quarters with an average surprise of 12.8%.
Currently, PFE has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: PFE beat on second quarter earnings which came in at 64 cents while our consensus called for EPS of 62 cents.
Revenue: Revenues were also above expectations. Pfizer posted revenues of $13.1 billion, compared to our consensus estimate of $12.9 billion. Unfavorable currency movement cut Pfizer’s second quarter revenues by 3% ($302 million).
Maintains Guidance: Pfizer continues to expect earnings of $2.38 - $2.48 per share on revenues of $51 billion - $53 billion. The Zacks Consensus Estimate for earnings and revenues are currently $2.46 per share and $52.6 billion, respectively.
PFIZER INC Price
PFIZER INC Price | PFIZER INC Quote
Check back later for our full write up on this PFE earnings report!
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>